Table 2 Proportion of data items reported
From: Guidelines are needed for studies of pre-treatment HIV drug resistance: a methodological study
# | Item | n (%) |
|---|---|---|
Study level data | ||
1 | Setting of study, e.g. hospital, community, prison etc. | 132 (56.4) |
2 | Location of study, e.g. country, city, village | 230 (98.3) |
3 | Study design, e.g. cross-sectional, retrospective etc. | 103 (44.0) |
4 | Sample size justification, i.e. (was the sample size justified?) | 6 (2.6) |
Participant data | ||
5 | Age | 186 (79.5) |
6 | Sex/Gender | 203 (86.8) |
7 | Sexual orientation | 179 (76.5) |
8 | Transmission risk group, e.g. injections drug use | 178 (76.1) |
9 | Profession | 9 (3.8) |
10 | Place of residence, e.g. urban, rural | 33 (14.1) |
11 | Ethnicity | 83 (35.5) |
12 | Level of education | 19 (8.1) |
13 | Income | 6 (2.6) |
14 | Exposure to antiretroviral therapy, e.g. treatment-naïve | 216 (92.3) |
Information on resistance testing | ||
15 | Type of resistance test, e.g. Sanger sequencing, next generation sequencing | 199 (85.0) |
16 | Mutation list used, e.g. aWHO SDRM list | 204 (87.2) |
17 | Number of genotypes (as opposed to the number of participants) | 134 (57.3) |
18 | Resistance to NNRTI drug class | 222 (94.9) |
19 | Resistance to NRTI drug class | 220 (94.0) |
20 | Resistance to PI drug class | 207 (88.5) |
21 | Resistance to INSTI drug class | 5 (2.1) |
22 | Clinical Relevance, e.g. mutations associated with reduced virological response | 52 (22.2) |
Other information | ||
23 | Source of funding | 195 (83.3) |